Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Receivables Refunds (2019 - 2025)

BioNexus Gene Lab's Receivables Refunds history spans 7 years, with the latest figure at $61384.0 for Q4 2025.

  • Quarterly results put Receivables Refunds at $61384.0 for Q4 2025, down 27.07% from a year ago — trailing twelve months through Dec 2025 was $61384.0 (down 27.07% YoY), and the annual figure for FY2025 was $61384.0, down 27.07%.
  • Receivables Refunds for Q4 2025 was $61384.0 at BioNexus Gene Lab, down from $103640.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $103640.0 in Q3 2025 to a low of $1767.0 in Q1 2022.
  • The 5-year median for Receivables Refunds is $40996.0 (2022), against an average of $42403.8.
  • Peak annual rise in Receivables Refunds hit 1641.44% in 2023, while the deepest fall reached 92.72% in 2023.
  • Year by year, Receivables Refunds stood at $2727.0 in 2021, then skyrocketed by 1056.99% to $31551.0 in 2022, then skyrocketed by 82.52% to $57588.0 in 2023, then surged by 46.15% to $84167.0 in 2024, then dropped by 27.07% to $61384.0 in 2025.
  • According to Business Quant data, Receivables Refunds over the past three periods came in at $61384.0, $103640.0, and $101471.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.